comprehensive -WSS

comprehensive

author：comprehensive 2025-09-27 22:05:38 - browse：276

Sarepta - Cambridge -AP — Kristoffer Tripplaar/Sipa via AP

The Food and Drug Administration granted conditional approval Thursday to the first gene therapy for Duchenne muscular dystrophy. Regulators restricted the treatment to younger patients, with additional data required to broaden its use.

The gene therapy, called Elevydis, is made by Sarepta Therapeutics. The company will charge $3.2 million for the treatment, making it the U.S.’s second most expensive drug, behind a recently approved gene therapy for hemophilia. CEO Doug Ingram said on a conference call the price was below what a recently published company-funded analysis found would be cost-effective.

“The approval of Elevidys is a watershed moment for the treatment of Duchenne. Elevydis is the first and only gene therapy approved for Duchenne, and this approval brings us closer to our goal of bringing forward a treatment that provides the potential to alter the trajectory of this degenerative disease,” Ingram said.

Unlock this article by subscribing to STAT+ and enjoy your first 30 days free!

GET STARTED Log In

Previous article： Trump demands the U.S. pay no more for drugs than other countries … again
Next article： A Q&A with Gavi’s Seth Berkley on vaccines, Covid, and more

WSS

US intelligence assessment says Iran not currently developing nuclear weapons

Affordable Connectivity Program vital to health care, experts say

Stanford president faces new allegations over 1999 paper

Kansas must stop changing trans people's sex listing on driver's licenses, judge says

With fresh data, a dynamic duo powers Eli Lilly to new heights

Indian pharmaceutical industry in denial over drug

leisure time

comprehensive

focus

Hollywood unions extend contract negotiations for actors

How redistricting in 6 states could affect who controls Congress

Walensky prepares to leave CDC — and Congress — behind

Florida group launches initiative to get abortion constitutional amendment on 2024 ballot

Alkermes shareholders re

The PBM ad wars are taking over Washington, D.C.

Over 800 arrested across France in 3rd night of riots after fatal police shooting of teen

7 more heat

Guidelines to prevent youth baseball injuries need more muscle

'Stay indoors': Escaped wild animal on the loose in Berlin prompts urgent citywide search

focus

Neutralizing antibodies against HIV shows promise in children

Indian pharmaceutical industry in denial over drug

Public funding for King Charles III and royals has been recalculated due to windfarm deal profits

Awakening the world to the whoosh: A patient's crusade

I learned firsthand about improving diversity in clinical trials

Senate committee advances SCOTUS ethics bill after alleged justice misconduct

knowledge

explore

Wikipedia

hotspot